参附注射液联合米托蒽醌为主的化疗治疗急性粒细胞白血病的临床分析

Chemotherapy mainly with Shenfu injection and mitoxantrone for acute myeloid leukemia

目的 探究参附注射液联合米托蒽醌为主的化疗治疗急性粒细胞白血病的有效性及安全性.方法 常规化疗组急性粒细胞白血病患者采用以米托蒽醌为主的MA方案,静脉滴注米托蒽醌10mg/ （m2·d）,第1～3d,阿糖胞苷100mg/ （m2·d）,连续滴注第1～7d.参附注射液组患者在上述MA化疗方案的基础上加滴参附注射液60 ml/d,连续滴注第1～ 14d.结果 参附注射液组患者化疗过程中的不良反应情况较轻.参附注射液组患者经治疗后WBC、Hb和PLT值均显著高于常规化疗组患者（P＜0.05）.治疗后参附注射液组患者的CD4、CD8和CD4/CD8值均明显高于常规化疗组患者（P＜0.05）.结论 参附注射液联合米托蒽醌为主的化疗对于急性髓系白血病患者的治疗具有显著减少患者不良反应、减轻化疗毒副作用、提高患者免疫力、增强疗效等优点,值得临床应用.

Objective To explore the effectiveness and safety of the chemotherapy mainly with Shenfu injection and mitoxantrone for acute myeloid leukemia.Methods The conventional chemotherapy group were treated with MA scheme：intravenously dripped mitoxantrone 10 mg/（m2 · d） from the first to third day and Ara 100 mg/（m2 · d） from the first to seventh day.In addition,the Shenfu injection group intravenously dripped Shenfu injection 60ml/d from the first to 14th day.Results The adverse effects of the Shenfu injection group were milder.After the treatment,the levels of WBC,Hb,and PLT and the values of CD4,CD8,and CD4/ CD8 were higher in the Shenfu injection group than in the conventional chemotherapy group （P 〈 0.05）.Conclusions Chemotherapy mainly with Shenfu injection and mitoxantrone for patients with acute myeloid leukemia can lower the incidence of adverse reactions,make the side effects of chemotherapy milder,promote patients＆#39; immunity,enhance curative effect,etc.and is worth being clinically applied.